Project UpdateMay 14, 2026, 07:32 AM
Agomab to Present AGMB-447 Preclinical Data at ATS Conference
AI Summary
Agomab Therapeutics announced its management team will participate in several upcoming industry and investor conferences. The company will present preclinical data for AGMB-447, an inhaled TGFβR1/ALK5 inhibitor for Idiopathic Pulmonary Fibrosis, at the ATS International Conference 2026, highlighting its robust anti-fibrotic activity and target engagement. Additionally, Agomab will hold fireside chats and investor meetings at other key events through July 2026, enhancing its visibility within the biopharmaceutical and investment communities.
Key Highlights
- Agomab to present preclinical data for AGMB-447 at ATS International Conference 2026 on May 20.
- Poster #904 highlights AGMB-447's robust anti-fibrotic activity and target engagement.
- Management to participate in H.C. Wainwright BioConnect Investor Conference on May 19.
- Company to hold fireside chat at RBC Capital Markets Global Healthcare Conference on May 20.
- Agomab to attend JPM European Healthcare Symposium on June 10.
- Company to participate in BIO International Convention from June 22-25.
- One-on-one investor meetings scheduled at Leerink Partners Therapeutics Forum on July 15.
Price Impact
More from AGMB